

INDIANA HEALTH COVERAGE PROGRAMS (IHCP) PHARMACY BENEFIT BONE FORMATION STIMULATING AGENTS PRIOR AUTHORIZATION REQUEST FORM



CareSource Pharmacy Prior Authorization Form P.O. Box 8738 Dayton, OH 45401-8738 Fax: (866) 930-0019

Today's Date	Non-Urgent: Urgent:		
Note: This form must be completed by the prescribing provider.			
All sections must be completed by the prescribing provider. Incomplete requests will be returned.			
Patient's CareSource ID #	Date of Birth / / /		
Patient's Name	Prescriber's Name		
Prescriber's IN License #	Specialty		
Prescriber's NPI #	Office Contact		
Prescriber Fax	Prescriber Phone		
Prescriber Address	Date(s) of Service: Start Date:	_	
Diagnosis	Diagnosis Code		
Requested Medication and Strength Dire	ctions for Use Treatment Dura	tion	
•	•		
PA Requirements for ALL Agents:			
Member has a diagnosis of osteoporosis? ☐ Yes ☐ No			
Member is 18 years of age or older? ☐ Yes ☐ No			
Select ONE of the following: Member has previously tried and failed bisphosphonate therapy Drug/dose/date(s) of use:			
☐ Member has specific medical rationale against use of bisphosphonate therapy Please explain:			
☐ Member has been determined to be a high risk patient as demonstrated by the World Health Organization (WHO) Fracture Risk Assessment Model			
Request is for renewal of therapy? Yes No If yes, provide date range or number of months member has received therapy: ———————————————————————————————————			

Forteo and Tymlos Will the total length of therapy exceed 2 years? Yes No If yes, provide medication rationale for continued use beyond two years.
Evenity Will the total length of therapy exceed 1 year? Yes No If yes, provide medication rationale for continued use beyond one year. ———————————————————————————————————
PA Requirements for FORTEO:
Provider attests that member has none of the following conditions and has not undergone prior radiation therapy: ' Yes No Bone metastases or skeletal malignancies Increased baseline risk for osteosarcoma Metabolic bone disease other than osteoporosis Paget's disease of bone Pre-existing hypercalcemia (Ca++>12mg/dL) If no, please specify if member has undergone prior radiation therapy and/or has any of the above conditions and provide medical rationale to justify requested therapy:
Prescriber Signature: Date:
PA Requirements for EVENITY:
 Provider attests that member has none of the following conditions:
If no, please specify if member has any of the above conditions and provide medical rationale to justify requested therapy:
Prescriber Signature: Date:
Prescriber Signature: Date:
Prescriber Signature: Date: Member has experienced menopause and is currently post-menopausal? □ Yes □ No

PA Requirements for TERIPARATIDE:
Provider attests that member has none of the following conditions or has undergone prior radiation therapy: Yes No Bone metastases or skeletal malignancies Increased baseline risk for osteosarcoma Metabolic bone disease other than osteoporosis Paget's disease of bone Pre-existing hypercalcemia (Ca++>12mg/dL)
If no, please specify if member has undergone prior radiation therapy and/or has any of the above conditions and provide medical rationale to justify requested therapy:
Prescriber Signature: Date:
Member has tried and failed brand Forteo? □ Yes □ No
Dates of use:
If no, provide medical justification for use over brand Forteo:
PA Requirements for TYMLOS:
Provider attests that member has none of the following conditions or has undergone prior radiation therapy: ☐ Yes ☐ No ☐ Bone metastases or skeletal malignancies ☐ Increased baseline risk for osteosarcoma ☐ Metabolic bone disease other than osteoporosis ☐ Paget's disease of bone ☐ Pre-existing hypercalcemia (Ca++>12mg/dL) If no, please specify if member has undergone prior radiation therapy and/or has any of the above conditions
and provide medical rationale to justify requested therapy:
Prescriber Signature: Date:
Member has tried and failed brand Forteo? □ Yes □ No
Dates of use:
If no, provide medical justification for use over brand Forteo:

CONFIDENTIAL INFORMATION

This facsimile and any attached document are confidential and are intended for the use of individual or entity to which it is addressed. If you have received this in error, please notify us by telephone immediately at 1-844-607-2831.